Triple Therapy with High‐Dose Proton‐Pump Inhibitor, Amoxicillin, and Doxycycline Is Useless for <i><scp>H</scp>elicobacter pylori</i> Eradication: A Proof‐of‐Concept Study

Almeida, Nuno; Romãozinho, José Manuel; Donato, Maria Manuel; Luxo, Cristina; Cardoso, Olga; Cipriano, Maria Augusta; Marinho, Carol; Sofia, Carlos

doi:10.1111/hel.12106

Cited by 19 publications

(19 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Doxycycline‐containing therapy has been used in the eradication of H. pylori as first‐line therapy, as second‐line therapy, and as third‐line rescue therapy. In those studies that used DOX as first‐line therapy for the eradication of H. pylori , the results were not satisfactory, with eradication rates ranging from 0 to 68% . In one study only, higher eradication rates could be reached using a unconventional quadruple therapy with DOX associated with levofloxacin, the sinthetic antiprotozoal nitazoxanide, and a PPI as first‐line therapy.…”

Section: Discussionmentioning

confidence: 99%

A Triple and Quadruple Therapy with Doxycycline and Bismuth for First‐Line Treatment of Helicobacter pylori Infection: A Pilot Study

et al. 2015

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

A Triple and Quadruple Therapy with Doxycycline and Bismuth for First‐Line Treatment of Helicobacter pylori Infection: A Pilot Study

et al. 2015

View full text Add to dashboard Cite

show abstract

“…moxifloxacin), some tetracyclines (doxycyclin) should not be used in HP treatment for their poor effectiveness (< 80%). (54,55). Their use is, therefore, discouraged.…”

Section: Basic Principlesmentioning

confidence: 99%

Guidelines for the management of Helicobacter pylori infection in Italy: The III Working Group Consensus Report 2015

Zagari

Romano

Ojetti

et al. 2015

Digestive and Liver Disease

118

149

View full text Add to dashboard Cite

Knowledge on the role of Helicobacter pylori (HP) infection is continually evolving, and treatment is becoming more challenging due to increasing bacterial resistance. Since the management of HP infection is changing, an update of the national Italian guidelines delivered in 2007 was needed. In the III Working Group Consensus Report 2015, a panel of 17 experts from several Italian regions reviewed current evidence on different topics relating to HP infection. Four working groups examined the following topics: (1) "open questions" on HP diagnosis and treatment (focusing on dyspepsia, gastro-oesophageal reflux disease, non-steroidal anti-inflammatory drugs or aspirin use and extra-gastric diseases); (2) non-invasive and invasive diagnostic tests; (3) treatment of HP infection; (4) role of HP in the prevention of gastric cancer. Statements and recommendations were discussed and a consensus reached in a final plenary session held in February 2015 in Bologna. Recommendations are based on the best current evidence to help physicians manage HP infection in Italy. The guidelines have been endorsed by the Italian Society of Gastroenterology and the Italian Society of Digestive Endoscopy.

show abstract

“…When doxycycline was used as first‐line therapy in different studies, the eradication rates ranged from 36%‐61% in triple therapies and 59.3%‐92.1% in quadruple therapies . As second‐line or third‐line rescue therapies, the eradication rates of triple therapies were similarly low (ranging from 0%‐40%), while the efficacies of quadruple therapies were between 67.4% and 91% . The abovementioned studies suggest that doxycycline should be used in quadruple therapy, especially in BQT, for higher eradication rates, rather than in triple therapy.…”

Section: Discussionmentioning

confidence: 99%

Bismuth, rabeprazole, amoxicillin, and doxycycline as first‐line Helicobacter pylori therapy in clinical practice: A pilot study

Chen

et al. 2019

Helicobacter

View full text Add to dashboard Cite

Background Bismuth‐containing quadruple therapy (BQT) is a recommended alternative first‐line therapy for Helicobacter pylori (H. pylori) infection. We aim to evaluate the efficacy and safety of a new BQT with amoxicillin and doxycycline as a first‐line treatment for H. pylori infection in clinical practice. Methods An open, prospective pilot clinical study including H. pylori‐positive outpatients who had never received eradication treatment was carried out. An RADB regimen (10 mg rabeprazole, 1000 mg amoxicillin, 100 mg doxycycline, and 220 mg colloidal bismuth tartrate, all given bid for 14 days) was prescribed by gastroenterologists. H. pylori eradication was confirmed by a 13C‐urea breath test performed at least 6 weeks after the end of treatment. Regimen efficacy was evaluated by per‐protocol (PP) and intention‐to‐treat (ITT) analyses. Results One hundred eighteen patients were included in the study. The eradication rate of RADB was 93.8% (105/112; 95% CI 89.2%‐98.3%) in PP analysis and 89.8% (106/118; 95% CI 84.3%‐95.4%) in ITT analysis. The patient compliance rate was 97.5% (115/118). The adverse event rate was 6.8% (8/118). Adverse events included asthenia, loss of appetite, dry mouth, heartburn, diarrhea, and abdominal pain. All adverse events disappeared after completion of therapy. Conclusion Our results suggest that 14‐day BQT with amoxicillin and doxycycline can be an effective and safe eradication regimen for first‐line therapy against H. pylori infection in clinical practice.

show abstract

Triple Therapy with High‐Dose Proton‐Pump Inhibitor, Amoxicillin, and Doxycycline Is Useless for Helicobacter pylori Eradication: A Proof‐of‐Concept Study

Abstract: Although safe, a triple-therapy protocol with high-dose PPI, amoxicillin, and doxycycline is useless for multidrug-resistant H. pylori eradication.

Cited by 19 publications

References 48 publications

A Triple and Quadruple Therapy with Doxycycline and Bismuth for First‐Line Treatment of Helicobacter pylori Infection: A Pilot Study

A Triple and Quadruple Therapy with Doxycycline and Bismuth for First‐Line Treatment of Helicobacter pylori Infection: A Pilot Study

Guidelines for the management of Helicobacter pylori infection in Italy: The III Working Group Consensus Report 2015

Bismuth, rabeprazole, amoxicillin, and doxycycline as first‐line Helicobacter pylori therapy in clinical practice: A pilot study

Contact Info

Product

Resources

About